You are invited a launch party and benefit for MDMA-assisted psychotherapy research in Fort Collins, Colorado, on Saturday, January 27, 2018.

Celebrate the launch of our new research site at the Wholeness Center in Fort Collins, where MDMA-assisted psychotherapy will be investigated as a treatment for posttraumatic stress disorder (PTSD) in a Phase 3 clinical trial.

Reserve your tickets today to network with like-minded people, meet movers and shakers in the psychedelic research community, enjoy light refreshments, and contribute to this vital and promising movement.

Purchase tickets: maps.org/fortcollins2018

MAPS Founder and Executive Director, Rick Doblin, Ph.D., will hold an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines, as valuable tools for inspiring creativity, for personal and spiritual growth, and for catalyzing resolutions to global and social conflicts.

Leading researchers will join in the discussion to highlight the progress of MAPS-sponsored clinical trials investigating MDMA-assisted psychotherapy as a treatment for posttraumatic stress disorder (PTSD).

—

Breakthrough Therapy Designation:

Preliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials, the final phase of research, as efficiently as possible.

Phase 3 trials require more clinical sites, more therapists, more patients, and more support. This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment, which would radically shift policy and public perception surrounding psychedelics.

—

Healing Trauma:

There is a need unmet by modern psychiatry that psychedelic-assisted therapies can fill. By supporting groundbreaking research with psychedelic therapies, we can work together toward healing millions of people suffering from PTSD.

We can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs.

—

Speakers:

MAPS Founder and Executive Director Rick Doblin, Ph.D., has a professional goal to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist.

Dr. Scott Shannon, a holistic physician, psychiatrist, acupuncturist, and teacher, will serve as the Principal Investigator Fort Collins PI at his clinic, Wholeness Center, which provides cross-disciplinary evaluation and care for mental health concerns. In 2001, Dr. Shannon published the first textbook on holistic psychiatry and continues to be published widely. He shares his knowledge as an Assistant Clinical Professor at the University of Colorado and through Psychiatry MasterClass, a program he was central in creating that provides professionals with in-depth education in integrative mental health.

Hania Withem was a participant in MAPS’ Phase 2 clinical trial of MDMA-assisted psychotherapy for posttraumatic stress disorder. Hania currently lives and works in Fort Collins, Colorado.

Purchase tickets: maps.org/fortcollins2018���
—

Questions? Contact [email protected]

Special thanks to our host committee (in formation): Jade Netanya Ullmann.

—

About MAPS:

The Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986, MAPS’ highest priority is to develop MDMA-assisted psychotherapy into an FDA-approved prescription treatment for PTSD.

�Learn about our research and other events at maps.org